The pharma manufacturing landscape in 2026 is more volatile than ever. Take part in this benchmarking study to see how your peers are responding.
Rapidly changing geopolitics. Capacity constraints. Pricing pressure. Technology disruption. The challenges facing biopharma sponsors and CDMO leaders are mounting, and the strategies that worked even 12 months ago may no longer be sufficient.
How are you and your peers responding?
That’s the question behind the CDMO Growth Report 2026, an independent research initiative from PharmaSource and Simon-Kucher & Partners designed to benchmark how the industry is navigating this critical moment.
The research will explore how biopharma sponsors and CDMO leaders are adapting their strategies across key areas: capacity planning, technology adoption, supply chain resilience, pricing approaches, and partnership models. The goal is to provide actionable insights into how leading organizations are responding to the current environment—and where the industry is heading.
Why participate?
By taking the 20-minute survey, you’ll gain early access to the findings before public release. All responses are strictly confidential, and the aggregated insights will help you benchmark your own strategy against industry peers.
The full results will be presented at CDMO Live Europe in Rotterdam (May 19-21, 2026) and CDMO Live Americas in Boston (October 19-21, 2026), where the insights will shape discussions about the future of external manufacturing partnerships.
